<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277627</url>
  </required_header>
  <id_info>
    <org_study_id>JAP-NEV-2010-01</org_study_id>
    <nct_id>NCT01277627</nct_id>
  </id_info>
  <brief_title>Influence of Nevirapine on HCV Viral Load</brief_title>
  <acronym>HELICON</acronym>
  <official_title>Influence of Nevirapine on HCV Viral Load Among HIV/HCV-coinfected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Valme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nevirapine-based antiretroviral therapy is associated with lower plasma HCV viral load in
      HIV/HCV-coinfected individuals.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in HCV viral load</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HCV Infection.</condition>
  <condition>HCV Viral Load.</condition>
  <arm_group>
    <arm_group_label>Nevirapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-nevirapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>nevirapine: 400 mg a day.</description>
    <arm_group_label>Nevirapine</arm_group_label>
    <arm_group_label>Non-nevirapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz, protease inhibitors</intervention_name>
    <description>efavirenz: 600 mg a day</description>
    <arm_group_label>Nevirapine</arm_group_label>
    <arm_group_label>Non-nevirapine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection.

          -  Older than 18 years.

          -  Chronic hepatitis C.

          -  Undetectable HIV viral load during one year before starting study.

          -  To have not received HCV therapy during one year before starting study.

          -  To have not started efavirenz or protease inhibitors o nucleoside analogs during 6
             months before starting study.

          -  Non contraindications for drugs included in this study.

          -  To change an antiretroviral regimen including efavirenz or protease inhibitors by
             nevirapine due to side effects, interactions or pregnancy (NVP group)

          -  To continue with a antiretroviral regimen including efavirenz or protease inhibitors
             (non-NVP group)

        Both groups will be matched according to these variables:

          -  Liver stiffness.

          -  HCV genotype.

          -  Hospital.

          -  Time from starting antiretroviral therapy.

          -  Previous third drug (EFV or PI) to introduction of NVP.

        Exclusion Criteria:

          -  HCV therapy during follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JOSE MIRA-ESCARTI, M.D</last_name>
    <phone>+34-955015363</phone>
    <email>miraescarti@yahoo.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Valme University Hospital</name>
      <address>
        <city>Seville</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JOSE A MIRA-ESCARTI, M.D</last_name>
      <phone>+34-955015363</phone>
      <email>miraescarti@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>JOSE A MIRA-ESCARTI, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>January 14, 2011</last_update_submitted>
  <last_update_submitted_qc>January 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>JOSE ANTONIO MIRA-ESCARTI</name_title>
    <organization>INFECTIOUS DISEASES UNIT, VALME UNIVERSITY HOSPITAL, SEVILLE, SPAIN</organization>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>HIV</keyword>
  <keyword>Nevirapine</keyword>
  <keyword>HCV viral load</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>Protease inhibitors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

